Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Zacks Investment Research on MSN9d
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.
The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may pose heightened risks for kidney, pancreatic, and gastrointestinal problems.
Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...
Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback